First RNAi Therapy Approved by FDA
Alnylam's patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news
More News: Amyloidosis | Science